PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic · Immunology

Access

Coverage of who can actually get diagnosis and treatment - payer dynamics, geographic variation, infrastructure constraints, and the international divergence that defines real-world access. 2 pieces on access in Immunology, newest first within each collection.

← All topics
FilterAll (58)Oncology (2)Rare Disease (8)Immunology (2)Neurology (25)Cardiometabolic (4)Respiratory (3)Women's Health (5)Mental Health (7)Ophthalmology (2)

Signals

1
SignalApr 26, 2026FDA · EMA · peer-reviewed

JAK class label restrictions are reshaping moderate-disease prescribing

FDA boxed warnings and EMA caution have repositioned JAK inhibitors as later-line agents in rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis - reshaping the practical sequencing decision in moderate disease.

TreatmentRegulatorySafetyAccess

Explained

1
ExplainedApr 26, 2026payer-policy · peer-reviewed · patient-advocacy

How payer step-therapy evolved from a cost tool into a sequencing rulebook

Step-therapy began as a way for payers to manage spend on competing biologics with similar efficacy. It has, over the past decade, become a de-facto sequencing rulebook that defines the order in which classes are tried regardless of which class fits the patient's phenotype best. The clinical and patient-experience consequences are larger than the cost-management origin would suggest.

AccessStep therapyBiologicsPayer